Zusammenfassung
Der Natrium-Jodid-Symporter (NIS) vermittelt als intrinsisches Membranprotein den aktiven Transport von Jodid nicht nur in die Schilddrüse sondern auch eine Reihe weiterer Organe, insbesondere die laktierende Brustdrüse. Aufgrund seiner zentralen Rolle beim thyreoidalen Jodtransport öffnete die Klonierung des NIS-Gens vor 6 Jahren ein neues, spannendes und breit gefächertes Kapitel in der Schilddrüsenforschung. Sie ermöglichte die Untersuchung der thyreoidalen und extrathyreoidalen Expression und Regulation von NIS, sowie die Charakterisierung seiner pathophysiologischen und therapeutischen Bedeutung bei benignen und malignen Schilddrüsenerkrankungen. Daneben bildet der Symporter die Grundlage der diagnostischen Schilddrüsenszintigraphie sowie der therapeutischen Anwendung von Radiojod bei der Behandlung von Schilddrüsenkarzinomen und ihrer Metastasen. Die Möglichkeit des gezielten NIS-Gentransfers in nichtthyreoidale Tumore und der Nachweis endogener NIS-Expression in der Mehrzahl der Mammakarzinome eröffnen darüber hinaus vielversprechende Perspektiven für die diagnostische und therapeutische Anwendung von NIS auch außerhalb der Schilddrüse.
Abstract
The sodium iodide symporter (NIS) is an intrinsic plasma membrane protein that mediates the active transport of iodide in the thyroid gland and a number of extrathyroidal tissues, in particular lactating mammary gland. Because of its crucial role in the ability of thyroid follicular cells to trap iodide, cloning of NIS opened an exciting and extensive new field of thyroid-related research. Cloning and molecular characterization of NIS allowed investigation of its expression and regulation in thyroidal and nonthyroidal tissues, and its potential pathophysiological and therapeutic implications in benign and malignant thyroid diseases. In addition, NIS-mediated iodide accumulation allows diagnostic thyroid scintigraphy as well as effective therapeutic application of radioiodine in benign and malignant thyroid disease. Characterization and application of NIS as a novel therapeutic gene for cytoreductive gene therapy of extrathyroidal tumors, and the presence of high endogenous NIS expression in the majority of breast cancers further suggest a promising role of NIS in diagnosis and therapy of cancer outside the thyroid gland.
Literatur
Carrasco N (1993) Iodide transport in the thyroid gland. Biochem Biophys Acta 1154: 65–82
Wolff J (1964) Transport of iodide and other anions in the thyroid gland. Physiol Rev 44: 45–90
Spitzweg C, Morris JC (2002) The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol 57: 559–574
Rodriguez AM, Perron B, Lacroix L et al. (2002) Identification and characterization of a putative human iodide transporter located at the apical membrane of thyrocytes. J Clin Endocrinol Metab 87: 3500–3503
Dai G, Levy O, Carrasco N (1996) Cloning and characterization of the thyroid iodide transporter. Nature 379: 458–460
Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL, Jhiang SM (1996) Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 226: 339–345
Smanik PA, Ryu K-Y, Theil KS, Mazzaferri EL, Jhiang SM (1997) Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 138: 3555–3558
Levy O, De la Vieja A, Carrasco N (1998) The Na+/I- symporter (NIS): Recent advances. J Bioenerg Biomemb 30: 195–206
Spitzweg C, Joba W, Eisenmenger W, Heufelder AE (1998) Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab 83: 1746–1751
Spitzweg C, Joba W, Schriever K, Goellner JR, Morris JC, Heufelder AE (1999) Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab 84: 4178–4184
Jhiang SM, Cho JY, Ryu KY et al. (1998) An immunohistochemical study of Na+/I- symporter in human thyroid tissues and salivary gland tissues. Endocrinology 139: 4416–4419
Tazebay UH, Wapnir IL, Levy O et al. (2000) The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med 6: 871–878
Spitzweg C, Dutton CM, Castro MR, Bergert ER, Goellner JR, Heufelder AE, Morris JC (2001) Expression of the sodium iodide symporter in human kidney. Kidney Int 59: 1013–1023
Josefsson M, Grunditz T, Ohlsson T, Ekblad E (2002) Sodium/iodide-symporter: distribution in different mammals and role of entero-thyroid circulation of iodide. Acta Physiol Scand 175: 129–137
Pinke LA, Dean DS, Bergert ER, Spitzweg C, Dutton CM, Morris JC (2001) Cloning of the mouse sodium iodide symporter. Thyroid 11: 935–939
Perron B, Rodriguez AM, Leblanc G, Pourcher T (2001) Cloning of the mouse sodium iodide symporter and its expression in the mammary gland and other tissues. J Endocrinol 170: 185–196
Kogai T, Curcio F, Hyman S, Cornford EM, Brent GA, Hershman JM (2000) Induction of follicle formation in long-term cultured normal human thyroid cells treated with thyrotropin stimulates iodide uptake but not sodium/iodide symporter messenger RNA and protein expression. J Endocrinol 167: 125–135
Kogai T, Endo T, Saito T, Miyazaki A, Kawaguchi A, Onaya T (1997) Regulation of thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology 138: 2227–2232
Levy O, Dai G, Riedel C, Ginter CS, Paul EM, Lebowitz AN, Carrasco N (1997) Characterization of the thyroid Na+/I- symporter with an anti-COOH terminus antibody. Proc Natl Acad Sci U S A 94: 5568–5573
Saito T, Endo T, Kawaguchi A, Ikeda M, Nakazato M, Kogai T, Onaya T (1997) Increased expression of the Na+/I- symporter in cultured human thyroid cells exposed to thyrotropin and in Graves' thyroid tissue. J Clin Endocrinol Metab 82: 3331–3336
Riedel C, Levy O, Carrasco N (2001) Post-transcriptional regulation of the sodium/iodide symporter (NIS) by thyrotropin. J Biol Chem 276: 21458–21463
Spitzweg C, Heufelder AE, Morris JC (2000) Thyroid iodine transport. Thyroid 10: 321–330
Wolff J, Chaikoff IL (1948) Plasma inorganic iodide as a homeostatic regulator of thyroid function. J Biol Chem 174: 555–564
Castro MR, Bergert ER, Beito TG, McIver BD, Goellner JR, Morris JC (1999) Development of monoclonal antibodies against the human sodium iodide symporter: Immunohistochemical characterization of this protein in thyroid cells. J Clin Endocrinol Metab 84: 2957–2962
Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, Schlumberger M, Bidart JM (1998) Na+/I- symporter distribution in human thyroid tissues: An immunohistochemical study. J Clin Endocrinol Metab 83: 4102–4106
Joba W, Spitzweg C, Schriever K, Heufelder AE (1999) Analysis of human sodium/iodide symporter, thyroid transcription factor-1, and paired-box-protein-8 gene expression in benign thyroid diseases. Thyroid 9: 455–466
Russo D, Bulotta S, Bruno R et al. (2001) Sodium/iodide symporter (NIS) and pendrin are expressed differently in hot and cold nodules of thyroid toxic multinodular goiter. Eur J Endocrinol 145: 591–597
Tonacchera M, Viacava P, Agretti P et al. (2001) Benign nonfunctioning thyroid adenomas are characterized by a defective targeting to cell membrane or a reduced expression of the sodium iodide symporter protein. J Clin Endocrinol Metab 87: 352–357
Spitzweg C, Morris JC (2000) The immune response to the iodide transporter. Endocrinol Metab Clin North Am 29: 389–398
Stanbury JB, Dumont JE (1983) Familial goiter and related disorders. McGraw-Hill, New York, pp 231–269
Pohlenz J, Refetoff S (1999) Mutations in the sodium/iodide symporter (NIS) gene as a cause for iodide transport defects and congenital hypothyroidism. Biochimie 81: 469–476
Kosugi S, Okamoto H, Tamada A, Sanchez-Franco F (2002) A novel peculiar mutation in the sodium/iodide symporter gene in Spanish siblings with iodide transport defect. J Clin Endorinol Metab 87: 3830–3836
Dohan O, Gavrielides MV, Ginter C, Amzel LM, Carrasco N (2002) Na/I symporter activity requires a small and uncharged amino acid residue at position 395. Mol Endocrinol 16: 1893–1902
Pohlenz J, Duprez L, Weiss R, Vassart G, Refetoff S, Costagliola S (2000) Failure of membrane targeting causes the functional defect of two mutant sodium iodide symporters. J Clin Endocrinol Metab 85: 2366–2369
Castro MR, Bergert ER, Beito TG, Roche PC, Ziesmer SC, Jhiang SM, Goellner JR, Morris JC (1999) Monoclonal antibodies against the human sodium iodide symporter: Utility for immunocytochemistry of thyroid cancer. J Endocrinol 163: 495–504
Castro MR, Bergert ER, Goellner JR, Morris JC (2001) Immunohistochemical expression of the sodium iodide symporter in differentiated thyroid caner: Correlation with131I uptake. J Clin Endocrinol Metab 86: 5627–5632
Patel A, Jhiang S, Dogra S et al. (2002) Differentiated thyroid carcinoma that express sodium-iodide symporter have a lower risk of recurrence for children and adolescents. Pediatr Res 52: 737–744
Schmutzler C, Winzer R, Meissner-Weigl J, Kohrle J (1997) Retinoic acid increases sodium/iodide symporter mRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 240: 832–838
Simon D, Koehrle J, Reiners C et al. (1998) Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary carcinoma. World J Surg 22: 569–574
Venkataraman GM, Yatin M, Marcinek R, Ain KB (1999) Restoration of iodide uptake in dedifferentiated thyroid carcinoma: Relationship to human Na+/I- symporter gene methylation status. J Clin Endocrinol Metab 84: 2449–2457
Kitazono M, Robey R, Zhan Z et al. (2001) Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86: 3430–3435
Spitzweg C, Harrington KJ, Pinke LA, Vile RG, Morris JC (2001) The sodium iodide symporter and its potential in cancer therapy. J Clin Endocrinol Metab 86: 3327–3335
Cho JY, Leveille R, Kao R et al. (2000) Hormonal regulation of radioiodide uptake activity and Na+/I- symporter expression in mammary glands. J Clin Endocrinol Metab 85: 2936–2943
Rillema JA, Yu TX (1996) Prolactin stimulation of iodide uptake into mouse mammary gland explants. Am J Physiol 271: E879–E882
Rillema JA, Rowady DL (1997) Characteristics of the prolactin stimulation of iodide uptake into mouse mammary gland explants. Proc Soc Exp Biol Med 215: 366–369
Rillema JA, Yu TX, Jhiang SM (2000) Effect of prolactin on sodium iodide symporter expression in mouse mammary gland explants. Am J Physiol Endocrinol Metab 279: E769–E772
Rillema JA, Williams CH, Moulden J, Golden KL (2001) Effect of insulin on iodide uptake in mouse mammary gland explants. Exp Biol Med 227: 32–35
Moon DH, Lee SJ, Park KY et al. (2001) Correlation between 99mTc-pertechnetate uptakes and expression of human sodium iodide symporter gene in breast tumor tissues. Nucl Med Biol 28: 829–834
Kogai T, Schultz J, Johnson L, Huang M, Brent G (2000) Retinoic acid induces sodium/iodide symporter gene expression and radioiodine uptake in the MCF-7 breast cancer cell line. Proc Natl Acad Sci U S A 97: 8519–8524
Cho JY, Shen DHY, Yang W et al. (2002) In vivo imaging and radioiodine therapy following sodium iodide symporter gene transfer in animal model of intracerebral gliomas. Gene Ther 9: 1139–1145
Groot-Wassink T, Aboagye EO, Glaser M, Lemoine NR, Vassaux G (2002) Adenovirus biodistribution and noninvasive imaging of gene expression in vivo by positron emission tomography using human sodium/iodide symporter as reporter gene. Human Gene Ther 13: 1723–1735
Spitzweg C, Zhang S, Bergert ER et al. (1999) Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res 59: 2136–2141
Spitzweg C, O'Connor MK, Bergert ER, Tindall DJ, Young CYF, Morris JC (2000) Treatment of prostate cancer by radioiodine therapy after tissue-specific expression of the sodium iodide symporter. Cancer Res 60: 6526–6530
Spitzweg C, Dietz AB, O'Connor MK, Bergert ER, Tindall DJ, Young CYF, Morris JC (2001) In vivo sodium iodide symporter gene therapy of prostate cancer. Gene Ther 8: 1524–1531
Dadachova E, Bouzahzah B, Zuckier LS, Pestell RG (2002) Rhenium-188 as an alternative to iodine-131 for treatment of breast tumors expressing the sodium/iodide symporter (NIS). Nucl Med Biol 29: 13–18
Petrich T, Helmeke HJ, Meyer GJ, Knapp WH, Pötter E (2002) Establishment of radioactive astatine and iodine uptake in cancer cell lines expressing the human sodium/iodide symporter. Eur J Nucl Med 29: 842–854
Carlin S, Mairs RJ, Welsh P, Zalutsky MR (2002) Sodium-iodide symporter (NIS)-mediated accumulation of (211At)astatide in NIS-transfected human cancer cells. Nucl Med Biol 29: 729–739
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Spitzweg, C. Der Natrium-Jodid-Symporter (NIS). Internist 44, 396–411 (2003). https://doi.org/10.1007/s00108-003-0877-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-003-0877-9